PATIENTS WHO WERE DIAGNOSED ≥10 YEARS BEFORE STARTING TREATMENT WITH OPZELURA
Select a Patient to
view their results
DIAGNOSED ≈30 YEARS BEFORE STARTING TREATMENT WITH OPZELURA1
- TIFFANIE
- FEMALE
- 37 YEARS OLD
- REAL-WORLD PATIENT
BASELINE
WEEK 9
WEEK 13
WEEK 25
Case details and photographs provided by patient.
Actual patient treated with OPZELURA. Not a clinical trial participant. Because this is a real-world patient, there may be other factors influencing treatment results, and individual results may vary. Patient was compensated for their participation.
Swipe to see more results.
DIAGNOSED ≈25 YEARS BEFORE STARTING TREATMENT WITH OPZELURA1
- SAM
- Female
- 32 years old
- Real world patient
BASELINE
≈WEEK 34
≈WEEK 52
≈WEEK 104
Case details and photographs provided by patient.
Actual patient treated with OPZELURA. Not a clinical trial participant. Because this is a real-world patient, there may be other factors influencing treatment results, and individual results may vary. Patient was compensated for their participation.
Swipe to see more results.
DIAGNOSED 37.9 YEARS BEFORE STARTING TREATMENT WITH OPZELURA1
- FEMALE
- 46 YEARS OLD
- CLINICAL TRIAL PARTICIPANT
WEEK 0
F-VASI Score: 1.5
WEEK 12
F-VASI Score: 0.25
WEEK 24
F-VASI Score: 0.3
80% IMPROVEMENT
FROM BASELINE.
Clinical trial participant. Individual results may vary.
Swipe to see more results.
DIAGNOSED 10.6 YEARS BEFORE STARTING TREATMENT WITH OPZELURA1
- MALE
- 44 YEARS OLD
- CLINICAL TRIAL PARTICIPANT
WEEK 0
F-VASI Score: 2.0
WEEK 12
F-VASI Score: 1.8
WEEK 24
F-VASI Score: 0.56
72% IMPROVEMENT
FROM BASELINE.
WEEK 52
F-VASI Score: 0.21
90% IMPROVEMENT
FROM BASELINE.
Clinical trial participant. Individual results may vary. No conclusions of efficacy or safety should be made based on the extension data.
Swipe to see more results.
DIAGNOSED 54.4 YEARS BEFORE STARTING TREATMENT WITH OPZELURA1
Selected images of nonfacial lesions included in the T-VASI for a trial participant whose repigmentation achieved T-VASI50 at Week 24. Photos do not represent all lesions.1
- FEMALE
- 66 YEARS OLD
- CLINICAL TRIAL PARTICIPANT
WEEK 0
T-VASI Score: 9.6
WEEK 12
T-VASI Score: 7.65
WEEK 24
T-VASI Score: 4.65
52% IMPROVEMENT
FROM BASELINE.
Clinical trial participant. Individual results may vary. T-VASI scores are calculated based on the total body. Not all lesions that contribute to the T-VASI score are shown.
Swipe to see more results.
DIAGNOSED 19.8 YEARS BEFORE STARTING TREATMENT WITH OPZELURA1
Selected images of nonfacial lesions included in the T-VASI for a trial participant whose repigmentation achieved T-VASI50 at Week 52. Photos do not represent all lesions.1
- FEMALE
- 48 YEARS OLD
- CLINICAL TRIAL PARTICIPANT
WEEK 0
T-VASI Score: 6.1
WEEK 24
T-VASI Score: 3.31
WEEK 52
T-VASI Score: 2.14
65% IMPROVEMENT
FROM BASELINE.
Clinical trial participant. Individual results may vary. T-VASI scores are calculated based on the total body. Not all lesions that contribute to the T-VASI score are shown. No conclusions of efficacy or safety should be made based on the extension data.
Swipe to see more results.
DIAGNOSED 19.7 YEARS BEFORE STARTING TREATMENT WITH OPZELURA1
Selected images of nonfacial lesions included in the T-VASI for a trial participant whose repigmentation achieved T-VASI50 at Week 104. Photos do not represent all lesions.1
- FEMALE
- 42 YEARS OLD
- CLINICAL TRIAL PARTICIPANT
WEEK 0
T-VASI Score: 9.3
WEEK 24
T-VASI Score: 8.49
WEEK 52
T-VASI Score: 7.13
WEEK 104
T-VASI Score: 3.96
57% IMPROVEMENT
FROM BASELINE.
Polarized images. Clinical trial participant. Individual results may vary. T-VASI scores are calculated based on the total body. Not all lesions that contribute to the T-VASI score are shown. No conclusions of efficacy or safety should be made based on the extension data.